

Date: September 1, 2023

A qui de droit, *To whom it may concern,*

Les tests NG Test® SARS-CoV-2 Ag, Ninonasal® 5 Professional et Ninonasal® Autotest sont capables de détecter la protéine de la nucléocapside des variants suivants du SARS-CoV-2 :

The NG Test® SARS-CoV-2 Ag, Ninonasal® 5 Professional and Ninonasal® Autotest are able to detect the nucleocapsid protein from the following SARS-CoV-2 mutants:

- "Alpha" (B1.1.7)
- "Beta" (B.1.351)
- "Gamma" (P.1)
- "Delta" (B.1.617.2)
- "Epsilon" (B.1.427 et B.1.429)
- "Mu" (B.1.621)
- "Lambda" (C.37)
- "Iota" (B1.526)
- "Kappa" (B1.617.1)
- "Eta" (B1.525)
- "Omicron" (B.1.1.529, BA.2, BA.4, BA.5, BA.2.75, BA.4.6, BA.2.3.20, BN.1, CH1.1, XBB, XBB.1.5, XBB.1.16, EG.5, BQ1, BQ.1.1, XBC, BF.7, BA.2.86)

NG Biotech s'engage à implémenter un programme de surveillance concernant les nouveaux variants potentiels du SARS-CoV-2 afin d'assurer la performance des tests.

NG Biotech commits on implementing a surveillance program on potential new SARS-CoV-2 mutants in order to ensure the performance of the test.

Au nom de NG Biotech, *For and on behalf of NG Biotech,*

Jean Baptiste BAUDIER

Directeur Affaires réglementaires
Regulatory affairs Director

NG BIOTECH
ZA Courbouton Secteur 1
Atelier Relais Le Tremplin
35480 GUIPRY - France
Tél. 02 23 30 17 83 - Fax 09 71 70 53 10
www.ngbiotech.com

